KYORIN Pharmaceutical Co. has entered into an exclusive license agreement with Hinge Bio for HB2198, new drug candidate for systemic lupus erythematosus, discovered by Hinge Bio. HB2198 is a humanized bispecific antibody discovered using Hinge Bio's GEM-DIMER technology platform.
KYORIN has obtained the exclusive rights in Japan to develop and commercialize HB2198 for the treatment of SLE and other diseases. KYORIN will make an upfront payment of $10 million to Hinge Bio. Hinge Bio is also eligible to receive milestone payments of up to $95 million.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.